AIxCrypto Holdings, Inc. 8-K

What Happened AIxCrypto Holdings, Inc. filed an 8-K (May 28, 2026) reporting significant leadership changes and the Board’s decision to discontinue its legacy biotechnology business. On May 21, 2026, Co‑CEO and director Kevin Richardson II resigned effective immediately; President Campbell Becher resigned effective immediately; and CFO and director Koti Meka resigned as a director effective May 21, 2026 and as CFO effective June 20, 2026. The Board appointed independent director Jie (Jay) Sheng to serve as President and Chief Financial Officer effective June 21, 2026 (Mr. Sheng ceased to be independent and left the audit committee immediately). The filing also reports new director appointments: Jerry Wang (director, effective May 21, 2026) and Chen Shi (independent director, expected to chair the Audit Committee).

Mr. Sheng’s offer (dated May 21, 2026) provides a $400,000 annual base salary, eligibility for a discretionary annual bonus up to $200,000, and recommends equity awards: RSUs valued at $312,000 vesting over four years and performance stock units valued at $208,000 subject to milestone achievement and Board/share‑availability approval.

Key Details

• Executive resignations announced May 21, 2026: Kevin Richardson II (Co‑CEO & director), Campbell Becher (President), and Koti Meka (director effective May 21; CFO role ends June 20, 2026).
• Jie (Jay) Sheng appointed President & CFO effective June 21, 2026; compensation: $400,000 base, up to $200,000 bonus; proposed RSUs $312,000 and PSUs $208,000 (subject to Board and share availability).
• Board approved structured wind‑down of the Company’s legacy biotechnology business on May 21, 2026; management is evaluating financial impact (possible charges, impairments, or other costs).
• Jerry Wang and Chen Shi were added to the Board effective May 21, 2026; Chen Shi is designated independent and likely to chair the Audit Committee.

Why It Matters

• Leadership turnover: simultaneous departures of the Co‑CEO, President and CFO are material governance events that can affect strategy execution and investor confidence; the filing notes no disagreements prompted the resignations.
• Financial and operational impact: the biotech segment wind‑down may result in charges, asset impairments, or other costs—management is still assessing the magnitude and will report details in upcoming periodic filings.
• Equity and dilution considerations: the incoming CFO’s compensation includes equity awards that require Board approval and available shares under the stock plan. Investors should watch forthcoming filings (10‑Q/10‑K) for quantified financial impacts, any interim operational disclosures, and confirmation of the equity grants and Board approvals.